ArticleFrontiers in oncology2026
A machine learning approach to identify optimal candidates for transarterial chemoembolization in unresectable HBV-related hepatocellular carcinoma complicated by first-branch portal vein tumor thrombus: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Portal vein tumor thrombus (PVTT) is a critical factor influencing prognosis and treatment allocation for Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, accurately selecting patients with unresectable HCC and first-order branch PVTT (PVTT1) who would benefit from transarterial chemoembolization (TACE) remains a significant clinical challenge. This study aimed to leverage machine learning to address this issue. Methods: We conducted a large-scale, retrospective multicenter study utilizing data from 15 tertiary hospitals in China (2012-2021). A Random Survival Forest (RSF) model was constructed to identify key prognostic variables and stratify risk among TACE-treated PVTT1 patients. Model performance was evaluated using the Area Under the Receiver Operating Characteristic Curve (AUC). To mitigate selection bias and confounding factors for survival comparisons, Propensity Score Matching (PSM) was performed. Results: Of the 3,948 patients enrolled, 763 constituted the TACE-PVTT1 group. The RSF model exhibited robust predictive accuracy for this group, identifying tumor size, tumor number, AST, INR, and age as the top five clinical predictors. Patients in the bottom risk-score tertile were classified as low-risk. Notably, the overall survival (OS) of this low-risk TACE-PVTT1 group was not significantly different from that of the 3,073 TACE-PVTT0 patients (P = 0.19), a finding that was maintained after PSM (P = 0.54). A multivariate Cox analysis confirmed that in this low-risk context, PVTT1 status was not a significant prognostic factor (P = 0.08575). Additionally, TACE conferred a significant survival advantage over sorafenib in patients with PVTT1. Conclusion: The integrated application of RSF and PSM can effectively identify low-risk candidates for TACE among patients with unresectable HCC and PVTT1. Our findings provide strong evidence that for this carefully selected patient subgroup, TACE offers survival outcomes comparable to those for patients without PVTT, highlighting the clinical utility of machine learning in guiding treatment decisions for this challenging disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.